IGF2BP3 and breast cancer: Moreover, silencing of METTL3 significantly reduced m6A modification in breast cancer (BC) cells, decreased PD-L1 mRNA stability, and inhibited PD-L1 expression via the m6A-IGF2BP3 axis, enhancing antitumor immunity by promoting T cell activation, infiltration, and reducing exhaustion [112].